2020
Electronic Health Records for Drug Repurposing: Current Status, Challenges, and Future Directions
Xu H, Li J, Jiang X, Chen Q. Electronic Health Records for Drug Repurposing: Current Status, Challenges, and Future Directions. Clinical Pharmacology & Therapeutics 2020, 107: 712-714. PMID: 32012237, PMCID: PMC10815929, DOI: 10.1002/cpt.1769.Peer-Reviewed Original Research
2019
Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing
Wu Y, Warner J, Wang L, Jiang M, Xu J, Chen Q, Nian H, Dai Q, Du X, Yang P, Denny J, Liu H, Xu H. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing. JCO Clinical Cancer Informatics 2019, 3: cci.19.00001. PMID: 31141421, PMCID: PMC6693869, DOI: 10.1200/cci.19.00001.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterCancer survivalMayo ClinicDrug repurposingNoncancer drugsElectronic health record dataCancer registry dataEHR dataClinical trial evaluationOverall cancer survivalUniversity Medical CenterHealth record dataElectronic health recordsTreatment of cancerClinical trialsDrug classesRegistry dataMedical CenterDrug effectsSignificant associationLongitudinal EHRNew indicationsPatientsCancerHealth records
2016
Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology
Hart T, Dider S, Han W, Xu H, Zhao Z, Xie L. Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology. Scientific Reports 2016, 6: 20441. PMID: 26841718, PMCID: PMC4740793, DOI: 10.1038/srep20441.Peer-Reviewed Original ResearchConceptsPrecision anti-cancer therapyMolecular basisAnti-cancer therapyStructural systems pharmacologyProtein-protein interactionsDrug target identificationNetwork biology analysisMolecular targetsInteractomic dataGenetic interactionsStructural proteomeGenetic networksKey molecular targetsPhenotypic responsesKinase targetsBiology analysisCancer mutationsPleiotropic effectsAnti-cancer effectsNetwork biomarkersTarget identificationGenetic biomarkersSystems pharmacology approachKey nodesTarget
2015
A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case
Huang L, Soysal E, Zheng W, Zhao Z, Xu H, Sun J. A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case. BMC Systems Biology 2015, 9: s2. PMID: 26100720, PMCID: PMC4474536, DOI: 10.1186/1752-0509-9-s4-s2.Peer-Reviewed Original Research
2014
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality
Xu H, Aldrich M, Chen Q, Liu H, Peterson N, Dai Q, Levy M, Shah A, Han X, Ruan X, Jiang M, Li Y, St Julien J, Warner J, Friedman C, Roden D, Denny J. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. Journal Of The American Medical Informatics Association 2014, 22: 179-191. PMID: 25053577, PMCID: PMC4433365, DOI: 10.1136/amiajnl-2014-002649.Peer-Reviewed Original ResearchConceptsType 2 diabetes patientsElectronic health recordsCancer patientsCancer mortalityDiabetes patientsEHR dataNon-diabetic cancer patientsCox proportional hazards modelDrug exposure informationOral hypoglycemic medicationsCharlson Comorbidity IndexNon-diabetic patientsUse of metforminCancer diagnosisHealth recordsSite-specific cancersBody mass indexProportional hazards modelVanderbilt University Medical CenterUniversity Medical CenterLarge electronic health recordHypoglycemic medicationsCause mortalityComorbidity indexInsulin useNetwork‐Assisted Prediction of Potential Drugs for Addiction
Sun J, Huang L, Xu H, Zhao Z. Network‐Assisted Prediction of Potential Drugs for Addiction. BioMed Research International 2014, 2014: 258784. PMID: 24689033, PMCID: PMC3932722, DOI: 10.1155/2014/258784.Peer-Reviewed Original Research